Table 8 Final classification of 11 interventions, based on NMA of interventions for patients with T2DM and CKD
Certainty of the evidence | Category | Intervention | Intervention vs placebo RR (95% CI) | Surface under the cumulative ranking curve |
|---|---|---|---|---|
MACE | ||||
High certainty (moderate to high certainty evidence) | Category 2: among the most effective | Liraglutide | 0.69 (0.58,0.82) | 0.904 |
Category 1: inferior to the most effective, or superior to the least effective | Efpeglenatide | 0.70 (0.53,0.93) | 0.850 | |
| Â | Sotagliflozin | 0.76 (0.66,0.87) | 0.773 | |
| Â | Canagliflozin | 0.78 (0.68,0.89) | 0.732 | |
| Â | Finerenone | 0.88 (0.80,0.97) | 0.484 | |
Category 0: among the least effective | Semaglutide | 0.83 (0.60,1.13) | 0.589 | |
| Â | Empagliflozin | 0.58 (0.25,1.36) | 0.456 | |
| Â | Dapagliflozin | 0.92 (0.77,1.11) | 0.381 | |
| Â | Albiglutide | 0.93 (0.73,1.18) | 0.374 | |
| Â | Exenatide | 1.03 (0.89,1.20) | 0.151 | |
| Â | Ertugliflozin | 1.09 (0.87,1.38) | 0.107 | |
Low certainty (low to very low certainty evidence) | Category 0/1: might be among the most/least effective | – | – | – |
Renal outcome | ||||
High certainty (moderate to high certainty evidence) | Category 2: among the most effective | Dapagliflozin | 0.59 (0.48,0.74) | 0.941 |
| Â | Empagliflozin | 0.65 (0.55,0.78) | 0.847 | |
| Â | Canagliflozin | 0.70 (0.58,0.83) | 0.765 | |
Category 1: inferior to the most effective, or superior to the least effective | Finerenone | 0.86 (0.79,0.93) | 0.437 | |
Category 0: among the least effective | Sotagliflozin | 0.82 (0.57,1.18) | 0.489 | |
| Â | Liraglutide | 0.87 (0.71,1.08) | 0.386 | |
| Â | Dulaglutide | 0.90 (0.77,1.16) | 0.321 | |
| Â | Exenatide | 0.98 (0.70,1.37) | 0.216 | |
Low certainty (low to very low certainty evidence) | Category 0/1: might be among the most/least effective | – | – | – |
HHF | ||||
High certainty (moderate to high certainty evidence) | Category 2: among the most effective | Ertugliflozin | 0.51 (0.34,0.76) | 0.863 |
Category 1: inferior to the most effective, or superior to the least effective | Empagliflozin | 0.59 (0.40,0.88) | 0.702 | |
| Â | Dapagliflozin | 0.56 (0.41,0.76) | 0.785 | |
| Â | Canagliflozin | 0.60 (0.48,0.75) | 0.703 | |
| Â | Sotagliflozin | 0.67 (0.52,0.85) | 0.557 | |
| Â | Liraglutide | 0.73 (0.56,0.97) | 0.427 | |
| Â | Finerenone | 0.79 (0.67,0.92) | 0.327 | |
Category 0: among the least effective | Exenatide | 1.10 (0.83,1.46) | 0.040 | |
Low certainty (low to very low certainty evidence) | Category 0/1: might be among the most/least effective | – | – | – |
ACD | ||||
High certainty (moderate to high certainty evidence) | Category 1: among the most effective | Liraglutide | 0.76 (0.62,0.93) | 0.872 |
| Â | Dapagliflozin | 0.81 (0.66,0.98) | 0.769 | |
Category 0: among the least effective | Canagliflozin | 0.83 (0.69,1.02) | 0.700 | |
| Â | Empagliflozin | 0.85 (0.58,1.42) | 0.624 | |
| Â | Finerenone | 0.90 (0.80,1.00) | 0.553 | |
| Â | Sotagliflozin | 0.99 (0.83,1.17) | 0.315 | |
| Â | Exenatide | 1.01 (0.84,1.22) | 0.258 | |
| Â | Ertugliflozin | 1.16 (0.75,1.79) | 0.156 | |
Low certainty (low to very low certainty evidence) | Category 0/1: might be among the most/least effective | – | – | – |
CVD | ||||
High certainty (moderate to high certainty evidence) | Category 1: among the most effective | Liraglutide | 0.69 (0.52,0.90) | 0.907 |
Category 0: among the least effective | Empagliflozin | 0.78 (0.55,1.11) | 0.704 | |
| Â | Dapagliflozin | 0.85 (0.65,1.13) | 0.565 | |
| Â | Canagliflozin | 0.87 (0.71,1.05) | 0.554 | |
| Â | Finerenone | 0.88 (0.76,1.02) | 0.510 | |
| Â | Ertugliflozin | 0.88 (0.66,1.18) | 0.507 | |
| Â | Sotagliflozin | 0.89 (0.72,1.10) | 0.484 | |
| Â | Exenatide | 1.10 (0.87,1.39) | 0.091 | |
Low certainty (low to very low certainty evidence) | Category 0/1: might be among the most/least effective | – | – | – |